This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Case Report

A Case of Akathisia After Switching From Branded to Generic High-Dose Olanzapine

Joseph F. Goldberg, MD

Published: April 15, 2012

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

As many established atypical antipsychotics lose patent exclusivity, use of generic atypical antipsychotics will expectably rise in light of cost. US Food and Drug Administration (FDA) approval of generic drugs requires demonstration of bioequivalence of a generic agent (specifically, a plasma C and area under the curve [AUC] falling within a 90% confidence interval of 80%-125% of that achieved with a branded formulation) but no required evaluation of efficacy or tolerability. Limited data make it difficult for clinicians to advise patients on when less-expensive generic formulations differ from branded drugs in efficacy or adverse effects.

J Clin Psychiatry 2012; 73(4): 497

© 2012 Physicians Postgraduate Press, Inc.’ ‹

Volume: 73

Quick Links:

Continue Reading…

Subscribe to read the entire article


Buy this Article as a PDF